| 标题 |
Roche′s Tecentriq plus Avastin is the first treatment combination to reduce the risk of cancer returning in people with certain types of early‐stage liver cancer in a phase Ⅲ trial[EB/OL]
|
| 网址 |
求助人暂未提供
|
| DOI |
暂未提供，该求助的时间将会延长，查看原因？
|
| 其它 | Roche Media & Investor Release. [Ad hoc announcement pursuant to Art. 53 LR] Roche′s Tecentriq plus Avastin is the first treatment combination to reduce the risk of cancer returning in people with certain types of early‐stage liver cancer in a phase Ⅲ trial[EB/OL].(2023-01-19)[2023-01-20]. https://www.roche.com/media/releases/med-cor-2023- 01-19. |
| 求助人 | |
| 下载 |
PDF的下载单位、IP信息已删除
(2025-6-4)
GingerF
小乐
NianWang
学术文献互助
kk_happy
AllRightReserved
molihuakai
贪玩的秋柔
OK
zhangwenkang
YifanWang
干净的琦
sanvva
晓效
1111
Kelley
Scorpia112
Rita
无极微光
CR7
皖公网安备34019202002308
